东方生物(688298) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥150,627,973.03, a decrease of 79.82% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was -¥107,191,567.22, representing a decline of 134.59% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was -¥113,854,291.00, down 135.46% from the previous year[5] - The basic earnings per share for Q3 2023 were -¥0.53, a decline of 128.80% compared to the same period last year[6] - Net profit for Q3 2023 was a loss of CNY 67,266,359.19, significantly down from a profit of CNY 3,086,360,281.06 in Q3 2022[24] - The total comprehensive income for the third quarter of 2023 was -42,388,332.53 CNY, compared to 3,155,529,845.05 CNY in the same period of 2022[25] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥9,169,985,725.49, a decrease of 14.33% compared to the end of the previous year[6] - The company's total assets decreased to CNY 9,169,985,725.49 in Q3 2023 from CNY 10,703,739,425.99 in Q3 2022[21] - Total liabilities for Q3 2023 were CNY 1,242,938,753.22, down from CNY 2,380,745,146.42 in the same quarter of 2022[20] - The total equity attributable to shareholders decreased to CNY 7,779,796,043.04 in Q3 2023 from CNY 8,162,845,699.44 in Q3 2022[20] Cash Flow - The cash flow from operating activities for the year-to-date period was -¥185.32 million, indicating a significant drop in cash received from sales[11] - Net cash flow from operating activities for the first nine months of 2023 was -1,619,675,103.24 CNY, compared to 1,898,330,416.44 CNY in the same period of 2022[29] - Cash inflow from operating activities totaled 728,268,484.72 CNY, while cash outflow was 2,347,943,587.96 CNY for the third quarter[29] - The ending balance of cash and cash equivalents was 4,844,939,391.44 CNY, down from 7,082,482,916.75 CNY in the previous year[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,221[13] - The largest shareholder, Anji Fulanglai Import and Export Trade Co., Ltd., holds 39,312,000 shares, representing 19.5% of the total shares[14] - Fangs Holdings Limited is the second-largest shareholder with 37,800,000 shares, accounting for 18.75%[14] - The top three shareholders collectively hold 48.56% of the company's shares[14] - The company has no known related party relationships among the top ten unrestricted shareholders[14] Research and Development - Research and development expenses for Q3 2023 amounted to ¥64,395,907.34, an increase of 22.36% year-on-year, accounting for 42.75% of operating revenue[6] - Research and development expenses for the first three quarters of 2023 were CNY 188,135,533.21, compared to CNY 400,235,056.53 in the same period of 2022[23] Revenue Decline Factors - The company faced a substantial decline in revenue due to the removal of COVID-19 testing product sales, leading to an overall revenue drop of 91.70% for the year-to-date period[10] - The company expects a significant decline in both operating revenue and net profit attributable to shareholders in 2023 compared to 2022[16] Other Financial Metrics - The weighted average return on net assets for the year-to-date period was -38.25%, reflecting the impact of declining net profit[11] - The company reported non-recurring gains of ¥2,991,495.60 for Q3 2023, primarily from government subsidies closely related to its normal business operations[8] - The company reported a significant increase in cash outflow for purchasing goods and services, totaling 1,373,748,907.99 CNY in the third quarter[29] - The net cash flow from investing activities was -221,811,053.75 CNY for the first nine months of 2023, compared to -695,367,323.21 CNY in the same period of 2022[30] - Cash inflow from financing activities was 701,000,000.00 CNY, with a net cash flow of 35,322,755.53 CNY for the first nine months of 2023[30]